<DOC>
	<DOCNO>NCT00037583</DOCNO>
	<brief_summary>The primary objective ) establish maximum tolerate dose ( MTD ) gemtuzumab ozogamicin combination cytarabine daunorubicin , b ) ass safety gemtuzumab ozogamicin give concurrently cytarabine daunorubicin .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Gemtuzumab Ozogamicin Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>All adult patient relapse refractory AML , well young de novo AML patient eligible study Relapsed , refractory , de novo AML patient allow Phase I study Phase II allow enrollment young de novo AML AML follow antecedent hematologic disorder ( myelodysplasia myeloproliferation ) great 2 month duration De novo patient M3 AML AML secondary exposure chemotherapy radiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Acute</keyword>
	<keyword>Myeloid</keyword>
	<keyword>Leukemia</keyword>
</DOC>